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Abstract
Background: The Expanded Programme on Immunisation (EPI) provides an effective way of delivering intermittent
preventive treatment for malaria (IPT) to infants. However, it is uncertain how IPT can be delivered most effectively to older
children. Therefore, we have compared two approaches to the delivery of IPT to Gambian children: distribution by village
health workers (VHWs) or through reproductive and child health (RCH) trekking teams. In rural areas, RCH trekking teams
provide most of the health care to children under the age of 5 years in the Infant Welfare Clinic, and provide antenatal care
for pregnant women.
Methods and Findings: During the 2006 malaria transmission season, the catchment populations of 26 RCH trekking clinics
in The Gambia, each with 400–500 children 6 years of age and under, were randomly allocated to receive IPT from an RCH
trekking team or from a VHW. Treatment with a single dose of sulfadoxine pyrimethamine (SP) plus three doses of
amodiaquine (AQ) were given at monthly intervals during the malaria transmission season. Morbidity from malaria was
monitored passively throughout the malaria transmission season in all children, and a random sample of study children
from each cluster was examined at the end of the malaria transmission season. The primary study endpoint was the
incidence of malaria. Secondary endpoints included coverage of IPTc, mean haemoglobin (Hb) concentration, and the
prevalence of asexual malaria parasitaemia at the end of malaria transmission period. Financial and economic costs
associated with the two delivery strategies were collected and incremental cost and effects were compared. A nested case-
control study was used to estimate efficacy of IPT treatment courses. Treatment with SP plus AQ was safe and well
tolerated. There were 49 cases of malaria with parasitaemia above 5,000/ml in the areas where IPT was delivered through
RCH clinics and 21 cases in the areas where IPT was delivered by VHWs, (incidence rates 2.8 and 1.2 per 1,000 child months,
respectively, rate difference 1.6 [95% confidence interval (CI) 20.24 to 3.5]). Delivery through VHWs achieved a substantially
higher coverage level of three courses of IPT than delivery by RCH trekking teams (74% versus 48%, a difference of 27%
[95% CI 16%–38%]). For both methods of delivery, coverage was unrelated to indices of wealth, with similar coverage being
achieved in the poorest and wealthiest groups. The prevalence of anaemia was low in both arms of the trial at the end of
the transmission season. Efficacy of IPTc against malaria during the month after each treatment course was 87% (95% CI
54%–96%). Delivery of IPTc by VHWs was less costly in both economic and financial terms than delivery through RCH
trekking teams, resulting in incremental savings of US$872 and US$1,244 respectively. The annual economic cost of
delivering at least the first dose of each course of IPTc was US$3.47 and US$1.63 per child using trekking team and VHWs
respectively.
Conclusions: In this setting in The Gambia, delivery of IPTc to children 6 years of age and under by VHWs is more effective
and less costly than delivery through RCH trekking clinics.
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Trials conducted in a number of sub-Saharan African countries
have shown that antimalarial chemoprophylaxis reduces malaria
morbidity and mortality in children and school absenteeism [1–5].
However, this approach to malaria control has rarely been
implemented widely owing to concerns over its possible effect on
the propagation of resistance to antimalarials, the development of
natural immunity to malaria, and logistic constraints [6,7]. To take
advantage of the protective effect of chemoprophylaxis whilst
reducing the possible adverse effect of chemoprevention on the
development of natural immunity to malaria, the concept of
intermittent preventive treatment (IPT) with an effective antima-
larial has been developed. IPT involves administration of a full
treatment dose of an antimalarial drug at specific times, regardless
of the presence or absence of malaria parasites. Since treatment is
only given intermittently, this intervention is less likely to interfere
with the development of natural immunity than sustained
chemoprophylaxis.
The IPT strategy was explored first in pregnant women (IPTp)
[8–10]. The success of IPTp in reducing maternal anaemia and
low birth weight generated interest in the use of IPT for the
prevention of malaria and malaria-associated anaemia in infants
(IPTi) [11]. Following a number of successful trials that showed
that IPTi with sulphadoxine pyrimethamine (SP) is safe and
reduces the incidence of malaria in the first year of life by about
30% [12], WHO now recommends IPTi as a malaria control
strategy in areas where the burden of malaria in infants is high and
where resistance to SP is low. However in many countries of the
Sahelian and sub-Sahelian regions of Africa where transmission of
malaria is highly seasonal, the main burden of malaria morbidity
and mortality is not in infants but in older children [13–15]. In
these countries, there is a need to find new methods for preventing
malaria in older children. IPT provides a possible way of doing
this.
IPT in children (IPTc) with SP, given alone or in combination
with artesunate (AS) or amodiaquine (AQ), reduced the incidence
of malaria in children under the age of 5 y in Mali [16] and
Senegal [17], countries with a short malaria transmission season,
and in an area of Ghana where the malaria transmission season is
longer [18]. In recent, large-scale trials conducted in Burkina Faso
and Mali, IPTc with SP plus AQ reduced the incidence of both
complicated and uncomplicated malaria in children under the age
of 5 y who slept under an insecticide-treated bednet (ITN) by
approximately 70% [19,20], indicating that this is a very
promising strategy for malaria control in areas where malaria
transmission is seasonal. However, in contrast to IPTi and IPTp,
which are delivered through established Expanded Programme on
Immunisation (EPI) and antenatal clinics, respectively, there is no
established system for delivery of IPTc.
In rural areas of The Gambia, there are two possible routes
through which IPT might be given to older children: reproductive
and child health (RCH) trekking teams and community (village)
health workers (VHWs). We have, therefore, undertaken a
randomised trial in which we compared the effectiveness of
delivery of IPTc to Gambian children 6 y of age and under by
VHWs or by RCH trekking teams.
Materials and Methods
Study Site and Population
Study participants were recruited from villages and hamlets on
the south bank of Upper River Region (URR), The Gambia. The
study was conducted between September 2006 and June 2007. In
this area, malaria transmission is highly seasonal, occurring mostly
during and immediately after the rainy season (July–November)
[21]. Usage of ITNs is relatively high with 58.5% of households
having at least one ITN in a survey undertaken in 2006 [22]. At
the time of this study, first-line treatment for uncomplicated
malaria in The Gambia was chloroquine plus SP. In 2001, the
PCR-corrected treatment failure rate in symptomatic children at
day 28 after the start of treatment with SP and chloroquine was
6% in the central part of the country [23]. Since 2008, first-line
treatment has been changed to lumefantrine-artemether (Coar-
tem, Novartis). The study protocol and CONSORT checklist can
be found in the supporting information (Text S1 and S2,
respectively).
Overall Study Design
The study was designed as an open-label, cluster randomised
trial with the unit of randomisation being the catchment
population of RCH trekking teams. There were 33 trekking
clinics in the study area on the south bank of URR of which 27
were in rural areas and visited by trekking teams from health
centres at Gambisara, Basse, or Fatoto. 26 rural trekking clinics
were selected for inclusion in the study (one was excluded to give
an equal number in each study arm). The catchment populations
of these clinics were grouped into three strata on the basis of the
number of children under 5 y of age in each catchment area, and
the average distance from the nearest health centre. It was
intended that only children under five would be enrolled. However
at the time of enrolment about 16% of the children enrolled were
more than 5 years. Hence the trial and the analysis were expanded
to include children up to and including the age of 6.
Within each stratum, clinic catchment areas were randomised,
using permuted blocks using the random number generator in
Stata version 10 (Stata Corporation), to receive IPTc delivered
either by a VHW or through the RCH trekking team. The
randomisation was well balanced with respect to distance from the
nearest health centre, population of children up to 6 y of age,
proximity to a main road, and quality of the road, factors that
might influence access to the intervention and to malaria diagnosis
and treatment. For all the villages in the study area, the nearest
health centre could be reached in less than 4 h by local transport
or was within a few hours walking distance.
Screening and Enrolment
Following discussions with the National Malaria Control
Programme (NMCP) and the URR district level health authorities,
members of the study team, accompanied by the district health
team, visited all villages in the study area, explained the purpose
and methods of the study, and answered questions during meetings
open to all villagers. During these meetings, consent was obtained
from the elders of all villages in the study area to participate in the
trial. Before the start of the study, field workers and investigators
carried out a census in each of the 172 villages in the study area
that agreed to participate in the trial. A list of all children living in
these villages who would be aged between 6 and 72 mo at the time
of the first treatment in September 2006 was obtained from this
database to ensure that all the children in the right age group were
considered for inclusion in the study. Families of prospective study
participants were visited at home, where more information was
provided about the trial and individual, written informed consent
for a child to participate in the trial was obtained from parents or
guardians. Exclusion criteria included known allergy to any
antimalarial drug or the presence of acute or chronic, clinically
significant pulmonary, cardiovascular, hepatic, or renal disease.
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and asked to keep records of all deaths, birth, immigrations, and
emigrations that occurred during the study period. Village
reporters were visited fortnightly by project field workers and
their records collected and checked. Deaths that occurred at home
were investigated with a standardised verbal-autopsy questionnaire
and cause of death established whenever possible [24].
Drug Administration
Drugs were delivered by either members of RCH trekking
teams or by VHWs. Study participants were observed for
approximately 30 min after dosing and, if vomiting occurred
within this period, it was recommended that the child take another
dose. RCH trekking teams visited each of the study villages
approximately once a month to administer routine EPI vaccines
and vitamin A. During the course of the intervention each trekking
team in the RCH arm of the trial comprised an average of ten staff
members, four of whom were provided by the study team to assist
with the intervention. Trekking teams comprised staff with varying
levels of training ranging from state enrolled nurses to volunteers.
Each member of the team employed by the Ministry of Health
received a salary supplement of US$28 per month (US$ 2006)
(about 47% of their salary) during the 3 mo of the intervention as
an incentive for the extra hours of work that administration of
IPTc incurred. Trekking team drivers received a supplement of
US$14 per month.
All villages in The Gambia with a population of approximately
400 or more have provision for a VHW who receives limited
training from the Ministry of Health on the recognition and
treatment of common illnesses including malaria. VHWs are
meant to be supported by their community and do not receive any
payment from the Ministry of Health. VHWs retain a small stock
of essential drugs, including antimalarials, but as these must be
purchased from a government pharmacy they frequently run out
of stock. Thus, for the period of the study, all VHWs in the study
were supplied with antimalarials by the project for the period of
the study. VHWs received US$11 per month (US$ 2006) during
the period of drug administration and a driver with a supplement
of US$14 per month to deliver drugs to the VHWs. VHW
supervisors did not receive any additional payment. Before the
start of the study, VHWs were trained for 5 d on how to distribute
monthly IPTc using drug treatment charts, recognise signs and
symptoms of malaria and their relation to severity of illness, and
maintain a compliance ledger. Study participants from villages
within the IPTc arm of the study but without a resident VHW
received IPTc from the nearest village with a VHW.
A system for recording drug administration that could be used
by a VHW was devised, which consisted of a treatment card held
by the mother or guardian of each child and an IPT register held
by the VHW or RCH trekking team. The treatment card and the
IPT register were labelled with the child’s, mother’s, and village’s
names and compound, and with demographic surveillance and
study numbers. A set of three sticky labels were preprinted with the
child’s identifiers and placed in an envelope that was stapled onto
the treatment card. The dosage of trial medication for each study
participant was indicated on a largely pictorial treatment card,
employed because of the low levels of literacy of some VHWs,
using coloured circles and semicircles (a full circle for one tablet
and semicircle for half a tablet). To ensure that a child did not
receive more doses of IPTc than they should, blue-coloured
treatment cards were issued to children in villages where IPTc was
to be delivered by VHWs and pink-coloured cards to those
allocated to receive medication from the RCH trekking clinic.
When a child presented to the VHW or RCH trekking clinic for
their monthly treatment, one sticky label was removed from the
envelope and attached to the IPTc register, the child’s identity
checked and trial medication SP (tablets containing 500 mg
sulfadoxine/25 mg pyrimethamine) (Microlabs) and AQ (200 mg
base tablets) (Microlabs) were given. A single dose of SP was given;
children aged 3–11 mo received one half tablet and a whole tablet
was given if a child was aged 1–6 y. AQ was given daily for 3 d:
one quarter of a tablet if a child was aged 3–11 mo, one half of a
tablet if aged 1–2 y, and a whole tablet if aged 3–6 y. SP and the
first dose of AQ were given under direct observation by the VHW
or member of the trekking team. The mother or carer was given
tablets for the second and third dose of AQ in a small plastic bag
and was asked to administer these on the following 2 d at home.
Children were given their tablets crushed, suspended in water, and
administered with a spoon. The solubility and drug content of the
SP and AQ tablets was confirmed by analysis with high
performance liquid chromatography undertaken at the London
School of Hygiene & Tropical Medicine.
Surveillance for Adverse Events
To determine the prevalence of adverse events following drug
administration, 15 children in each cluster selected from the
participant database by simple random sampling were visited at
home within a week of the start of each round of drug
administration by a trained field worker who completed an
adverse event questionnaire. Parents and guardians of study
children were encouraged to take their child to the study nurse
based in the village or to the Medical Research Council (MRC)
clinic at Basse if the child became unwell between visits. Any
adverse reaction was graded by trained field workers as mild
(grade 1) if it was easily tolerated, moderate (grade 2) if it interfered
with normal activity, and severe (grade 3) if it prevented normal
activity and required treatment. In addition, records were kept of
all deaths and hospital admissions among study children during
the period of the trial. A serious adverse experience was defined as
any event that was fatal, life threatening, disabling or incapaci-
tating or resulted in hospitalisation, prolonged a hospital stay, or
was associated with overdose (either accidental or intentional). A
decision was made by the study physician as to whether a serious
adverse event was likely to be drug related.
Morbidity Surveillance during the Rainy Season
Passive surveillance for malaria was maintained throughout the
malaria transmission season (September to December). In both
arms of the trial, study children had 24-h access to medical
treatment provided by VHWs based in key villages or by study
nurses based in the health centres within the study area. In both
arms of the study, VHWs were asked to refer study participants
who presented to them to the nearest health facility for evaluation.
Each time a study patient presented to a health facility, axillary
temperature was recorded using a digital thermometer and
haemoglobin (Hb) concentration was measured using a portable
haemoglobinometer (HemoCue AB). The Core Malaria Pf test
(CORE Diagnostics), based on detection of circulating Plasmodium
falciparum histidine-rich protein 2 antigen, which is sensitive and
specific for detection of P. falciparum in whole blood samples, was
used to diagnose malaria if fever (axillary temperature $37.5uC)
or a history of fever within the previous 48 h was present. In such
cases, a thick blood smear was also collected for subsequent
confirmation of the diagnosis and estimation of parasite density.
Study participants with documented fever or history of recent
fever and malaria parasitaemia were treated with Coartem.
Treatment of study participants seen at the health centres for
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guidelines.
A cross-sectional survey was undertaken in all 26 clusters at the
end of the malaria transmission season. Children in each cluster
were selected for review by simple random sampling from the list
of study participants. The families of children selected for review
were visited at home, and follow-up visits made to find children
who were not present at the first visit. The first 40 children to be
located in each cluster were included in the survey. Children
included in the survey were examined, their axillary temperature
measured, and their height and weight recorded. A finger-prick
blood sample was taken for preparation of thick smears and
measurement of Hb concentration. The dates of IPT treatments
received were recorded from the child’s identification (ID) card,
and the mother or career was asked about reasons for missed
treatments, about the acceptability of the most recent round of
treatment, and about compliance with the unsupervised doses.
The families of the same children were visited 2–3 wk later and
asked questions about household assets, level of education and
sources of income of the child’s primary care giver, the care giver’s
perception of the relative wealth of the household, bednet use by
the study child, and asked to inspect the place where the child
usually slept and to inspect the condition of their net if a net was
being used.
Case-Control Study
In order to estimate efficacy of IPTc, a nested case-control
approach was used. Cases were children who presented to one of
the study health centres with an axillary temperature $37.5uCo r
a history of fever in the previous 48 h and who had malaria
parasitaemia with a parasite density $5,000/ml on initial reading.
Controls (initially two per case and subsequently one per case)
were selected from among children who presented to the same
health centre with a febrile illness in the same week that the case
was detected, who had a negative blood film, and whose village of
residence was in the same delivery arm (VHW or RCH) as the
case child. Cases and controls were visited at home to inspect the
place where the child slept, to ask the child’s mother or carer about
bednet use at the time that the case child became sick, and about
household assets. Dates of IPT treatment courses were obtained
from the child’s ID card and cross-checked against study registers.
Laboratory Methods
Thick smears were stained with Giemsa stain and 200 high
power fields (HPFs) were examined before a smear was declared
negative. Parasite density was expressed per microlitre with the
assumption that one parasite per HPF equals a density of 500
parasites per microlitre [25]. All slides were read independently by
two laboratory technicians. If there was disagreement between
their readings on parasite positivity or if the difference in the log10
densities recorded was more than 1.5, slides were read by a third
technician. Agreement was reached among the three technicians
after the slides had been rechecked. Discrepancies occurred mainly
in smears with very low parasite densities. Hb concentration was
measured during morbidity surveillance and at the survey at the
end of the malaria transmission season using a portable
haemoglobinometer (Hemocue AB).
Collection of Cost Data
A standard ingredients approach was used to cost the value of
each unit of input needed to deliver IPTc and to treat inpatient or
outpatient malaria episodes [26,27]. We report both financial costs
(additional government expenditure) and economic costs (the costs
of all resources needed to deliver IPTc regardless of funding
sources). For both the VHW and RCH trekking team, IPTc
delivery costs were broken down by categories including IPTc
drugs, non-IPTc drugs, drug dispensing, drug distribution,
supervision, training, and supplies. In addition, household costs
of receiving IPTc were based on a questionnaire completed by a
sub sample of 15 participants attending each of the 26 maternal
and child health clinic sites (n=390). Fieldworkers were asked to
stagger their interviews over the course of the day to ensure that
care givers accessing IPTc at various times could be included.
To reflect potential health system savings associated with fewer
malaria episodes, economic costs of treating malaria were based
on detailed retrospective cost data from health facilities across
primary, secondary, and tertiary level health facilities in the study
area between 2006 and 2007. Resource use associated with
personnel, materials and supplies, equipment, transport, utilities,
and buildings were recorded. Costs were identified using
information found in patient folders, facility stock records, activity
data collected by the district medical team, discussions with health
facility personnel (both medical and administrative), and compo-
nents of the study budget. Potential savings to households (direct
and indirect), such as reduced expenditure on transport and other
out-of-pocket expenses and potential savings in time lost from
seeking treatment were collected from the families of all study
children who were admitted to a hospital or health centre and
from the families of a subsample of 100 children treated as
outpatients. Costs are reported in 2008 US$.
In order to calculate the incremental cost-effectiveness ratios,
the costs of delivering IPTc via RCH trekking teams were
compared with the costs of delivery by VHWs and this difference
in costs was then compared to the following additional effects: (i)
number of malaria episodes averted; (ii) number of children
receiving the first dose of all three treatments; and (iii) number of
children who received the first dose of at least one treatment. For
ethical reasons, no placebo group was included in the current
study so it was not possible to compare cost-effectiveness of these
two strategies to current practice. Net cost effectiveness was
calculated for each delivery system by subtracting resources saved
from the total programme compared to the relevant outcome
measure.
Data Management
Data from participants were recorded on forms and were
checked by field supervisors, the study physician, and the data
manager for consistency and accuracy. All data were entered into
an SQL database using MS Access front-end software. The
accuracy of data input was checked and validated using
customized validation programmes. In addition, source data
verification was done by the data manager. The cleaned data
were converted to Stata version 10 file (Stata Corporation) prior to
analysis.
Statistical Analysis
The primary study endpoint was the incidence of malaria
(documented fever [axillary temp $37.5uC] or a history of fever
within the previous 48 h accompanied by asexual malaria
parasitaemia at a density of $5,000 parasites/ml) observed during
the study period. Secondary endpoints were the incidence of a
febrile illness with parasitaemia at any density, coverage of three
IPTc treatment courses, the proportion of children who received
no IPTc, the incidence of adverse events reported after IPTc
administration, the mean Hb concentration, and the prevalence of
asexual parasitaemia in the cross-sectional survey undertaken at
the end of the malaria transmission season. The study was
designed to determine whether delivery of IPTc through RCH
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as delivery by VHWs, and the sample size was calculated on this
basis. On the basis of previous studies carried out in The Gambia,
we assumed that 75% coverage with three IPT treatment courses
would be achieved in both arms, that the efficacy of IPT would be
90%, and that the incidence rate of malaria by passive case
detection would be 0.2 per child per transmission season without
IPT. The predicted cumulative incidence of malaria would
therefore be 6.5%, and we assumed that malaria incidence in
each cluster would range from 0% to 20%. With 26 clusters and a
cluster size of 500 children per cluster, the study was designed to
have 90% power to show (using a 95% confidence interval [CI])
that the difference in cumulative incidence between the delivery
methods was not more than 3.5%. Similar calculations were done
for coverage of IPTc, using a noninferiority margin of 10% to
15%, and for mean Hb at the end of the transmission season, using
a margin of 0.5 g/dl. An analysis plan was agreed before the data
were analysed.
The primary analysis included all children in the correct age
range who were present in the study area at the initial census and
were issued with a malaria card, regardless of the number of
treatments received.
Characteristics ofall childrenenrolledinthestudywere tabulated
by study arm, overall estimates (not adjusting for clustering) are
presented.For theprimaryoutcomeofmalariaincidenceduringthe
study period, analysis was by intention to treat. Time at risk was
calculated from September 11 to December 8 (the surveillance
period) or until date of death or emigration. All episodes of malaria
were included in the calculations; only two children had two
episodes ofmalaria. The incidence of malariain each study armwas
calculated as the total number of cases divided by the total time at
risk. The point estimate of the rate difference between the two arms
was the difference between these rates and a 95% CI adjusting for
clustering, and strata was calculated from the variances of the
stratified ratio estimates [28]. An adjusted rate difference was
calculated using a two-stage approach [29]. Both individual and
village-level covariates (child’s age, sex and ethnicity, and village
population and distance to nearest health centre) were included in a
Poisson regression model, the adjusted rate difference and 95% CI
were then estimated from the model residuals. Some covariates
likely to be prognostic for malaria risk, for example net use, were
only measured after the intervention period and on a subset of
children and were therefore not adjusted for.
For the analysis of the efficacy of IPTc against clinical malaria
using thecase-controlapproach,since some cases had parasitaemias
,5,000/ml on definitive reading, two case definitions of malaria
were used: a febrile illness accompanied by malaria parasitaemia of
any density or by malaria parasitaemia at a density $5,000 per ml.
The efficacy of an IPTc course given within the previous 28 d in
preventing malaria was estimated as 1006(121/OR) in which OR
is the odds ratio estimated by conditional logistic regression relating
case/control status to IPTc. Bednet usage (defined as usually slept
underanintactortreatednet,and the netcould betuckedunderthe
mattress), age, ethnicity, self-reported wealth, and distance to the
nearest health centre were considered as potential confounders. In a
secondary analysis, interaction with bednet usage was assessed using
alikelihoodratiotest,todeterminewhethertherewasanydifference
in the benefit of IPTc in children using bednets compared to
children not using nets. Interactions with delivery method and
socioeconomic variables were also assessed.
Coverage with IPTc was evaluated in the cross-sectional sample
survey conducted at the end of the study. The proportions of
children who had received each monthly treatment course, those
who received three treatment courses, and those who received no
treatment were tabulated. Differences in coverage estimates
between trial arms were estimated by calculating the arithmetic
mean of coverage proportions in each cluster, and conducting a
two-way analysis of variance, allowing for stratification.
To determine whether one delivery method was better at
reaching particular subgroups of the population, the coverage
indicators were tabulated, stratified by wealth, and by age of each
child. Wealth quintiles were calculated as quintiles of the scores on
the first component from principal components analysis of
household asset ratings (based on household ownership of ten
items), as recorded in the cross-sectional survey.
Numbers of adverse events were tabulated by study arm, and
risk differences with 95% CIs were calculated adjusting for
clustering and strata using analysis of variance on the arithmetic
cluster means, as described above. Outcomes collected at the
December cross-sectional survey were also analysed using the
analysis of variance method described above.
Ethical Review
The study was approved by the London School of Hygiene &
Tropical Medicine ethics committee and by the joint MRC/
Gambia Government ethics committee. The conduct of the trial
was guided by a Data Safety and Monitoring Board. The trial was
registered on the NCHS clinical trials database (number
NCT00376155).
Results
Baseline Comparability
12,326 children aged 6 mo to 6 y were enrolled into the study,
of whom 6,076 were in the RCH arm and 6,250 in the VHW arm
(Figure 1). Baseline characteristics of children in each arm of the
study are shown in Table 1. The number and age distribution of
children in the two study groups were similar. Observations made
during the cross-sectional survey undertaken at the end of the
malaria transmission season suggested that a slightly higher
proportion of children in the VHW arm slept under a bed net
compared to those in the RCH arm and that more children in the
VWH group were fully vaccinated compared to those in the RCH
arm.
Coverage Achieved with the Two Delivery Methods
On the basis of data collected during the cross-sectional survey
undertaken at the end of the surveillance period, 92% and 86% of
participants issued with a malaria card at time of the census
reported for enrolment and received the first IPTc treatment in the
VHW and RCH arms, respectively. More children in the VHW
arm received three treatment courses compared to the RCH arm
(74% versus 48%, a risk difference of 27% [95% CI 16%–38%]).
Coverage was higher in the VHW arm than in the RCH arm for
each monthly treatment round (Figure 1). In the RCH arm,
coverage was initially high but decreased progressively (Table 2).
In the VHW arm, coverage was slightly lower in November than
in September and October. During the November treatment
round, 98% of children were reported to have received both
additional AQ doses at home, and 5% of those who received
treatment were reported to have vomited the drug. These figures
were similar for each delivery method. For both delivery methods,
coverage with the three treatments was similar in each
socioeconomic group defined by wealth quintiles derived from
household assets. In the VHW arm, coverage of three courses of
IPT was 76% in the wealthiest quintile and 73% in the poorest
quintile; in the RCH arm coverage of three courses was 40% in
the wealthiest quintile and 48% in the poorest quintile.
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18 study children died during the surveillance period, nine in
each study arm. In the VHW group, five children died of severe
pneumonia, two children died of acute gastroenteritis, one child
died of cerebral malaria, and one from the complications of severe
malnutrition. In the RCH arm, three children died of severe
pneumonia, two died of malnutrition, two of acute gastroenteritis,
and two of severe malaria. 68 study children were admitted to one
of the health facilities in the study area during the follow-up
period; 30 and 36 in the RCH and VHW groups, respectively.
The main causes of admissions were malaria and pneumonia. 24
children were diagnosed with severe malaria, 14 in the RCH
group and 10 in the VHW group. 30 children were diagnosed with
pneumonia, 13 and 17 in the RCH and VHW groups,
respectively. None of the deaths or hospital admissions was
considered to be related to drug administration. There were no
deaths or hospital admissions associated with severe skin lesions
and no deaths suggestive of a blood dyscrasia.
Field workers visited 838 study participants within the first week
after the start of IPT treatment to document the incidence of adverse
reactions. The treatment regimen was generally well tolerated. The
mostfrequentlysolicited adverseeventsreported after treatment were
fever,vomiting, diarrhoea, and abdominal pain, which were reported
by 24%, 12%, 13%, and 5% of children, respectively. Seven children
reported a rash but in no child was this severe.
Incidence and Prevalence of Malaria in the Two Study
Populations
VHWs in the study area presumptively treated 288 study
participants for malaria (160 in VHW group, 128 in RCH group);
these were mainly those whose parents/guardians were unable or
were unwilling to travel to health centre. There were 49 cases of
Figure 1. Trial profile.
doi:10.1371/journal.pmed.1000409.g001
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IPTc was delivered through RCH clinics and 21 cases in the
communities where IPT was delivered by VHWs, (incidence rates
2.8 and 1.2 per 1,000 child months, rate difference 1.6 [95% CI
20.24 to 3.5]), and 144 cases with any parasitaemia in the RCH
areas compared to 81 in the VHW areas (rate difference 3.7 [95%
C1 20.7 to 8.1) (Table 3).
1,096 children were seen during the December 2006 survey at
the end of the malaria transmission season (Table 4). Very few
children were parasitaemic; the proportion of children who had
positive blood slides was similar in both groups (3.3% in the RCH
group and 2.3% in the VHW group) and fewer children had
malaria parasitaemia of $5,000 parasites/ml (0.6% in the RCH
group and 1.1% in the VHW group). Splenomegaly was also very
infrequent, being present in 1.8% and 1.3% of children in the
RCH and VHW groups, respectively. Mean Hb concentration
was similar in each group (10.3 g/dl RCH group versus 10.4 g/dl
VHW group). The proportions of children with moderate anaemia
(Hb ,7 g/dl) were 6.1% and 4.8% among children in RCH and
VHW groups, respectively.
Efficacy of IPTc in Preventing Clinical Episodes of Malaria
81 cases of malaria and 89 controls were recruited into the case-
control study (73 cases had one control and eight cases had two
controls). 56 case-control sets came from villages in the RCH study
area and 25 from villages in the VHW study area. 18 cases had
parasitaemia ,5,000/ml on definitive reading of a blood film. 20
(32%) of the 63 cases with parasitaemia $5,000/ml had received
an IPT course in the 28 d prior to the date the case was detected,
compared to 64% (45/70) among controls. All 65 cases and
controls who received an IPT course in the 28 d prior to case
detection reported full compliance with the additional home-
administered AQ doses. The crude estimate of protective efficacy
was 82%, and after adjustment for potential confounding effects of
bednet use, age, ethnicity, self-reported wealth, and distance to
nearest health centre, the efficacy of any IPTc treatment received
within the previous 28 d against a febrile illness accompanied by
malaria parasitaemia $5,000/ml was 87% (95% CI 54%–96%).
When cases with parasitaemia ,5,000/ml were included, adjusted
efficacy was 80% (95% CI 42%–93%). There was no evidence of
an interaction between the efficacy of IPTc and bednet use.
Cost and Cost Effectiveness of IPTc Delivery
Table 5 shows the total financial and economic costs of
delivering IPTc via either the RCH trekking teams or through
VHWs. The unit costs of delivering IPTc are presented in Table 6.
The financial costs are low using either delivery strategy because
certain costs associated with IPTc drug delivery and supervision
did not necessitate additional government expenditure as these
activities were already provided routinely. The difference in drug
costs reflects the difference in adherence, but even with lower
adherence and therefore lower drug costs, IPTc delivery was more
costly overall using RCH trekking teams than when delivered by
VHWs. The highest percentage of the total costs associated with
delivery by the RCH trekking teams was the costs of drug delivery
during the EPI clinics. This difference reflects the higher salary
costs (a senior enrolled nurse is paid a salary of approximately
US$60 monthly) and the US$28 monthly incentive required to pay
trained health care professionals to deliver IPTc. This cost can be
compared to the US$11 per month ‘‘incentive’’ given to the VHW
for administering IPTc. The highest financial cost component of
the VHW strategy was the delivery of non-IPTc drugs. Training
costs were similar for both the RCH and the VHW delivery
strategies. A total of 20 health care professionals needed to be
trained for delivery through the RCH trekking teams compared to
Table 1. Baseline characteristics of the children in the two
study groups.
Baseline Characteristics RCH Delivery
VHW
Delivery
Total population 40,115 38,681
Number of children #6 y 6,076 6,250
Age (mo)
,12 480 (7.9%) 470 (7.5%)
12–23.9 1,243 (20.5%) 1,281 (20.5%)
24–35.9 1,161 (19.1%) 1,181 (18.9%)
36–47.9 1,149 (18.9%) 1,241 (19.9%)
48–59.9 1,021 (16.8%) 1,072 (17.2%)
$60 1,022 (16.8%) 1,005 (16.1%)
Gender (48 missing)
Male 3,071 (50.6%) 3,165 (50.9%)
Ethnic group (65 missing)
Fula 1,986 (32.8%) 1,985 (32.0%)
Sarahule 2,671 (44.1%) 2,914 (46.9%)
Mandingo 1,288 (21.3%) 1,222 (19.7%)
Others 107 (1.8%) 88 (1.4%)
n Clusters 13 13
n Villages 89 80
Village population size (mean, range) 446 (13–4,758) 478 (6–4,251)
Total n VHWs 13 18
Mean (range) distance to nearest health
centre (km)
14.2 (3–34) 13.9 (4–30)
doi:10.1371/journal.pmed.1000409.t001
Table 2. Coverage of monthly IPT treatments achieved with delivery of IPTc by RCH trekking teams or by VHWs.
Monthly IPT Treatments RCH (n=511) VHW (n=550) Difference (95% CI)
a
Received September treatment (7 missing) 437 (86.0%) 503 (92.1%) 6.6% (20.3% to 13.6%)
Received October treatment (7 missing) 357 (70.3%) 493 (90.3%) 20.3% (13.1%–27.6%)
Received November treatment (6 missing) 314 (61.7%) 460 (84.2%) 22.1% (12.3%–32.0%)
Received 3 treatments (9 missing) 242 (47.8%) 406 (74.4%) 26.7% (15.6%–37.9%)
Received 0 treatments (9 missing) 36 (7.1%) 11 (2.0%) 25.2% (29.1% to 21.3%)
aAdjusted for clustering and strata.
doi:10.1371/journal.pmed.1000409.t002
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community. From a household cost perspective, none of the 390
care givers who were interviewed reported direct costs associated
with receiving IPTc and only one reported a loss in actual earnings
while accessing IPTc.
In terms of cost-effectiveness, this incremental analysis shows
that the VHW strategy is both more effective and less costly that
the RCH approach. Comparing VHWs against the RCH trekking
team there are three positive incremental effects: a reduction in the
number of malaria episodes averted by 63, an improvement in the
number of fully adherent children by 1,429, and an improvement
in the number of children who received at least one treatment by
251. The VHW strategy is also less costly in both economic and
financial terms than the RCH approach, resulting in incremental
saving of US$872 and US$1,244, respectively, on the basis of
intervention costs alone. When we include both intervention costs
(the costs of delivering IPTc) and health system savings (the costs
averted by fewer in- and out-patient malaria episodes) savings
increase to US$1,070 and US$1,443 in economic and financial
terms, respectively. Finally, when household savings due to the
reduction in malaria treatment costs are also added, by selecting
the VHW approach over the RCH approach, the incremental
savings increase further to US$1,148 and US$1,521 in economic
and financial terms, respectively.
Discussion
The efficacy results of this trial are consistent with findings from
previous studies of IPTc carried out in other West African
countries, which have shown significant levels of protection against
clinical attacks of malaria during the malaria transmission season
[16–20]. It was not considered appropriate to include a placebo
group in this study because of the clear evidence from previous
studies that IPTc is beneficial. However, using a case-control
approach, the intervention appeared to be highly efficacious in
preventing clinical episodes of malaria with a protective efficacy
for an IPT course given within the previous month of over 80%, a
figure comparable to that observed in a randomised controlled
trial undertaken in neighbouring Senegal [17]. The prevalence of
parasitaemia at the end of the malaria transmission season, when
this is normally at its highest, was very low in both sets of villages
(,3%) and much lower than the rate recorded in the study area in
Table 3. Incidence of clinical episodes of malaria in the two study groups.
Episodes RCH VHW
Rate Difference
(95% CI)a
Adjusted Rate
Difference
(95% CI)b
Total
Events
Child Months
at Risk
Incidence Rate/
1,000 Child
Months
Total
Events
Child
Months at
Risk
Incidence Rate/
1,000 Child
Months
Episodes with .5,000
parasites per ml
49 17,561 2.79 21 18,055 1.16 21.63 (23.49 to
0.24)
21.49 (23.17 to
0.18)
Episodes with any asexual
stage parasitaemia
144 17,561 8.20 81 18,055 4.49 23.71 (28.12 to
0.70)
23.89 (27.48 to
20.29)
aAdjusted for clustering and strata.
bAdjusted for child’s age, sex, and ethnicity; village population and distance to nearest health centre; clustering and strata.
doi:10.1371/journal.pmed.1000409.t003
Table 4. Results of end of rainy season cross-sectional survey.
Results RCH (n=525) VHW (n=571) Difference
a (95% CI)
P. falciparum parasitaemia $5,000 parasites/ml (23 missing) 4 (0.8%) 6 (1.1%) 0.3% (21.2% to 1.8%)
Any P. falciparum parasitaemia (23 missing) 17 (3.3%) 13 (2.3%) 21.1% (25.1% to 3.0%)
Geometric mean density (95% CI) of positive slides 337 (69–1,648) 478 (55–4,190)
Splenomegaly (60 missing) 9 (1.7%) 7 (1.3%) 20.8% (22.9% to 1.4%)
Mean Hb concentration (SD) 10.2 (2.0) 10.4 (2.0) 0.16 (20.22 to 0.54)
Anaemia (Hb ,11 gm/dl; 9 missing) 314 (59.9%) 325 (57.7%) 21.8% (29.5% to 5.9%)
Moderate anaemia (Hb ,7 gm/dl; 9 missing) 32 (6.1%) 27 (4.8%) 21.2% (24.5% to 2.2%)
Height-for-age z-score ,2 2 SD 93 (21.5%) 112 (23.4%) 3.7% (22.6% to 10.0%)
Weight-for-age z-score ,2 2 SD 152 (30.5%) 156 (31.3%) 2.5% (25.0% to 10.2%)
Weight-for-height z-score ,2 2 SD 98 (22.9%) 93 (19.4%) 20.4% (27.9% to 7.1%)
Usually sleeps under a bednet (32 missing) 314 (64%) 379 (71%)
Usually sleep under an intact or treated net
b (32 missing) 252 (51%) 343 (64%)
Children aged $12 mo who are fully vaccinated (97 missing) 289 (69%) 371 (79%)
aAdjusted for clustering.
bStrata treated in the last 12 mo or intact, and can be tucked under a mattress.
SD, standard deviation.
doi:10.1371/journal.pmed.1000409.t004
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been highly efficacious. However, these low incidence and
prevalence figures must be set in the context of an overall, recent
decline in the incidence of malaria in The Gambia associated with
a high use of ITNs and introduction of more effective treatment
[15].
In The Gambia delivery of IPTc by VHWs proved to be more
effective than delivery by RCH trekking teams as judged by the
level of coverage achieved. This finding is in agreement with the
findings of a small-scale study that investigated different options
for the delivery of IPTc in Ghana. This study also found that the
proportion of children who received at least the first dose of three
or more courses of IPTc was slightly higher in the community-
based arm compared to delivery by health workers at health
centres or at EPI outreach clinics (facility based) [31]. In keeping
with the finding that more effective coverage was achieved by
VHWs than by the trekking teams, the incidence of malaria, as
determined by passive case detection, was less in villages where
IPTc was delivered by VHWs than in those where RCH trekking
teams were used.
Delivering IPTc through community-based VHWs has several
advantages. VHWs are resident in the community, making drug
administration easy, and they can remind mothers/guardians if
they do not come for treatment. Children were able to receive
their medication on any day of the month. In contrast, children in
the RCH arm were able to receive their treatment only once a
month during the monthly visit of the trekking team, which may
explain the lower coverage observed in the RCH arm of the study
in October and November. Thus, operationally, VHW delivery is
less restrictive and more convenient for parents and guardians. A
previous study carried out in The Gambia showed that that
VHWs were able to achieve a high level of coverage of
antimalarial chemoprophylaxis among children and that in about
50% of the study villages, an acceptable level of compliance was
sustained for a period of 5 y, despite minimal outside supervision
and support for the programme [32]. Delivering IPTc through the
community-based VHWs proved to be the most effective
approach in The Gambia; however, this may not be the case in
other areas. Thus, there is a need to determine the optimum
delivery method in other settings.
A potential weakness of the trial was that it was not a placebo
controlled. It was not considered appropriate to include a placebo
group in this study because of the clear evidence from previous
studies in neighbouring Senegal and elsewhere that IPTc is
beneficial. Efficacy of the intervention was estimated using a
nested case-control study and, although this is not as rigorous as a
randomised trial, the estimates of efficacy were similar to those
obtained in previous trials. A further possible limitation is that,
although care was taken to ensure balanced randomisation, we did
not have prior data on malaria incidence in the study villages, and
an imbalance cannot be ruled out. However, the difference in
incidence of malaria between the study arms is consistent with the
Table 5. Total costs and cost effectiveness by delivery strategy (US$ 2008).
Categories Provider Costs Via RCH Trekking Teams Provider Costs Via VHWs
Financial Costs
a Economic Costs Financial Costs Economic Costs
US$ Percent US$ Percent US$ Percent US$ Percent
Costs
Cost of IPTc Drugs 835 17 835 14 1,050 28 1,050 21
Cost of non-IPTc Drugs 887 18 887 15 1,144 30 1,144 22
Drug dispensing 2,072 41 2,072 35 676 18 1,184 23
Drug delivery
- Personnel — — 1 0 — — 64 1
- Transport — — 262 4 — — 152 3
Supervision
- Personnel 276 5 429 7 138 4 160 3
- Transport — — 465 8 — — 454 9
Training 517 10 559 9 511 13 608 12
Supplies 454 9 454 8 279 7 279 5
Gross intervention cost: 5,042 100 5,966 100 3,798 100 5,093 100
Incremental saving
b
Intervention savings 1,244 872
Intervention and provider treatment savings 1,443 1,070
Intervention, provider, and household treatment savings 1,521 1,148
ICERs
c
Saving per malaria episodes averted 1,9.76 13.84
Saving per fully adherent child 0.87 0.61
Saving per child who received at least one dose 4.96 3.48
aFinancial costs reflect the additional resources required to deliver IPTc in terms of the actual expenditures incurred. Economic costs capture the opportunity cost of all
resources used to provide IPTc, whether or not they incur a financial cost.
bIncremental estimates reflect the cost savings of VHW over RCH trekking teams and compare these to the additional effects.
cIncremental cost effectiveness ratios (ICERs) are calculated on the basis of intervention costs only.
doi:10.1371/journal.pmed.1000409.t005
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doses, and so these may not have been important sources of bias. It
has to be noted, however, that the CI for the difference in malaria
incidence is wide (a general decline in malaria transmission meant
there were fewer events than we had anticipated when planning
sample size). A further potential source of bias in this study is that
VHWs were involved in IPTc delivery and this may have
influenced their treatment or referral of suspected malaria patients.
No serious adverse event attributable to study medication was
observed following administration of about 30,000 courses of SP
and AQ, adding to the increasing body of evidence that this drug
combination is safe when used for IPTc in African children. No
serious skin lesions were observed and there were no clinical cases
suggestive of a blood dyscrasia, although, as white cell counts were
not done routinely, the possibility that a blood dyscrasia
contributed to one of the fatal infections that occurred among
study children cannot be completely excluded. The overall
mortality rate among the children in the study was approximately
1.5 per 1,000 during the 4-mo period of observation, which
included, the period when most childhood deaths occur in The
Gambia, a figure well below that expected on the basis of previous
studies conducted in URR [14]. The most frequent minor adverse
events reported were fever, diarrhoea, vomiting, and malaise.
Reports of vomiting probably included some children who spat out
the medicine in reaction to the unpleasant taste of AQ. Since there
was no control group, it was not possible to assess the relationship
of the adverse events observed in this trial to study drugs and many
apparent side effects were likely to have been due to associated
infections, which are common during the rainy season. Develop-
ment of a liquid paediatric formulation would facilitate adminis-
tration of IPT and might reduce minor adverse events and
increase compliance.
We selected SP plus AQ as the combination to be used for IPTc
in this study because a trial undertaken in Senegal, which
compared four different treatment regimens, showed that the best
results were obtained with this regimen [33]. However, because of
increasing levels of resistance to SP and the unpalatability of AQ,
there is a need to find alternative drugs for IPTc. A recent trial
carried out in Senegal showed that combinations containing
piperaquine were safe and equally effective in preventing malaria
[34] and similar observations have been made in The Gambia
[35].
At between US$3.47 (using trekking teams) and US$1.63 (using
VHWs), the annual economic cost of delivering at least the first
dose of each treatment of IPTc under trial conditions are
comparable to the range of the costs associated with delivering
other malaria interventions. For example, the costs per year of
protection in US$ 2008 are reported to be US$1.46–US$4.00 for
ITNs [36], US$3.62–US$6.06 for indoor residual spraying (IRS)
[37], US$0.75 for IPT in infants using SP [38] and US$2.02 for
IPT in school children [39].
This study has shown the influence of scale on delivery of IPTc.
A smaller study of IPTc delivery gave unit costs of village-based
delivery more than three times higher than those presented here
[40], even after taking into account differences in costs of IPTc
drugs and of treating cases of malaria. In the present much larger
study, including over 12,000 children, certain fixed costs such as
incentives to VHWs and facility-based staff are divided by a much
larger number of children. Semi-fixed costs such as training, drug
delivery, and supervision also benefit from economies of scale in
The Gambia.
There are many potential ways in which VHWs can contribute
to the health of the communities in which they are based. These
ways include treatment of common infections, recognition and
referral of seriously ill patients, provision of advice on hygiene and
nutrition, and encouraging women to attend antenatal clinics and
to immunize their children. Community volunteers are also being
used increasingly as a route of delivery for mass treatment
campaigns against infections such as onchcocerciasis, intestinal
helminth infections, shistosomiasis, filariasis, and trachoma. In the
case of malaria, VHWs can provide treatment for clinical attacks
of malaria (home management of malaria) (HMM) either
presumptively or following the use of an RDT. They can
encourage the use of ITNs and, as we have shown in this study,
effectively administer IPTc. In countries, such as The Gambia,
where malaria transmission is seasonal, this activity in required for
only a few months of the year. However, although the incidence of
malaria in The Gambia, and countries with a similar epidemiol-
ogy, is concentrated within just a few months of the year,
occasional cases do occur at other times of the year and require
treatment. Thus, a logical approach is to ask VHWs to combine
the role of HMM throughout the year with the administration of
IPTc during the high transmission season. This approach has
recently been explored in The Gambia [41] and shown to be
effective and evaluated in Ghana where the malaria transmission
season extends over a longer period of the year [31].
Sustainability is a major concern for all interventions, especially
those that depend upon volunteers. Given the renewed focus on
VHWs and their ever-expanding repertoire of services [42], a
system must be identified to ensure that they are adequately
trained and supported and not given more tasks than they can
cope with [43]. The issue of training frequency and supervision
intensity, both for IPTc specifically, and in combination with the
other VHW tasks needs further investigation, as it will have
implications on both health and cost outcomes. As a component of
the trial, VHWs were supplied with antimalarials, oral rehydration
solution (ORS), and paracetamol syrup, thus strengthening their
role in the community in general. How to guarantee the routine
supply of these medicines outside trial settings, especially in
settings where health facility stock-out are common, will need
more evaluation.
Whether volunteers should be offered incentives to encourage
sustainability is debated. Some mass drug delivery systems have
been successful without incentives whilst others have employed
financial incentives of some kind. In The Gambia, the tradition
has been that VHWs should be supported by their community, an
approach that has not been particularly successful over the years in
many villages, leading to some VHWs becoming disillusioned due
to lack of financial and nonfinancial support. In Gambia VHW
can be paid US$7.50 per day for participation in mass drug
administration, polio, or vitamin A campaigns. In this study,
VHWs received an incentive of $11 per month. It is highly likely
this financial payment and the strengthened drug supply
contributed to the trials success. However, even with a small
financial payment the cost effectiveness of IPTc is still comparable
to that of other malaria interventions. Any incentives must reach
the VHW in a timely and efficient manner to avoid demotivation.
Longer term experience will show whether the high level of
coverage obtained in this study can be sustained but the results of
this trial suggest that community volunteers can achieve high level
coverage with this very effective malaria control intervention if
they are supported to do so.
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Background. In sub-Saharan Africa, malaria kills 800,000
people, the majority of whom are children, every year.
Intermittent preventive treatment (IPT) of malaria is an
effective malaria control strategy. IPT involves administration
of antimalarial drugs at defined time intervals to individuals
regardless of whether they are known to be infected with
malaria to prevent morbidity and mortality from the
infection. IPT was initially recommended for pregnant
women (IPTp) who are given at least two doses of
suphadoxine pyrimethamine (SP) during antenatal visits
after the first trimester of pregnancy. IPT is also effective in
infants (IPTi) and recently IPTi has been rolled out with the
administration of three doses of an antimalarial drug during
the expanded program of immunization visits. Clinical
studies have also shown that IPT is effective at reducing
malaria incidence in children (IPTc) by administering SP
alone, or in combination with artesunate (AS) or
amodiaquine (AQ,) over three intervals during the peak
malarial season.
Why Was This Study Done? The inclusion of IPTp in
antenatal visits and IPTi in the expanded program of
immunization has effectively scaled up these interventions
to the population level. So far, IPTc has only been
administered to children within the confines of clinical
trials—there is currently no established system for delivery of
IPTc. For the scale-up of IPTc to be successful, there needs to
be an appropriate point of entry and the roll out of a delivery
system that can be generalized to most settings in sub-
Saharan Africa. In order to address this issue, the researchers
conducted a randomized trial to compare the effectiveness
of IPTc delivery to children up to 6 y of age by village health
workers (VHW) or by reproductive and child health (RCH)
trekking teams (run by the Ministry of Health) in rural areas
of The Gambia.
What Did the Researchers Do and Find? During the
2006 malaria transmission season, the researchers randomly
allocated the catchment populations of 26 RCH clinics, each
with 400–500 children 6 y of age and under, to receive IPT
from an RCH trekking team or from a VHW. Before the trial
started, the researchers, accompanied by the district health
team, visited all villages in the study area to explain the
purpose and methods of the study and to obtain consent
from the elders of all participating villages. Eligible children
were treated with a single dose of SP plus three doses of AQ
given at monthly intervals during the malaria transmission
season. The researchers passively monitored malaria
incidence throughout the transmission season and at the
end of the malaria season, examined a random sample of 40
children from each cluster to measure their temperature,
height, and weight and to take a finger-prick blood sample
to measure blood hemoglobin and parasite levels (by
microscopy of thick blood smears). The researchers
recorded the financial costs associated with each delivery
strategy (mostly on the basis of staff pay and the financial
incentives given to VHWs).
There were 49 cases of clinical malaria in the areas where IPT
was delivered through RCH clinics and 21 cases in the areas
where IPT was delivered by VHWs. In addition, VHW delivery
of IPTc achieved a higher coverage level of three courses of
IPT than delivery by RCH trekking teams (74% versus 48%).
The prevalence of anemia was low in both arms at the end of
the transmission season. Delivery of IPTc by VHWs was
cheaper than delivery through RCH trekking teams, resulting
in incremental savings of US$872 and US$1,244, respectively.
The annual economic cost of delivering at least the first dose
of each course of IPTc using the RCH trekking team was
US$3.47 per child and with VHWs was US$1.63 per child.
What Do These Findings Mean? The results of this study
show that in rural areas of The Gambia, delivery of IPTc by
VHWs is more effective and less costly than delivery by RCH
trekking teams through RCH clinics. Delivering IPTc through
community-based VHWs versus monthly visits by the RCH
team has several advantages: VHWs are resident in the
community, making drug administration easy and flexible (as
children were able to receive their medication on any day of
the month), and they can remind mothers/guardians to
attend for treatment. Therefore, operationally, VHW delivery
is less restrictive and more convenient for parents and
guardians.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000409.
N This topic is further discussed in two PLoS Medicine
research articles by Dicko et al. and Konate ´ et al., and a
PLoS Medicine Perspective by Beeson
N WHO provides information about The Gambia
N WHO also provides information about the health work-
force, including the role of village health workers
N Roll Back Malaria has information about malaria in children,
including intervention strategies
N Unicef also provides comprehensive information about
malaria in children
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